Differential effects of HIF2α antagonist and HIF2α silencing in renal cancer and sensitivity to repurposed drugs

BACKGROUND: In clear cell renal cell carcinoma, 80% of cases have biallelic inactivation of the VHL gene, leading to constitutive activation of both HIF1α and HIF2α. As HIF2α is the driver of the disease promoting tumour growth and metastasis, drugs targeting HIF2α have been developed. However, resi...

Descripción completa

Detalles Bibliográficos
Autores principales: Arnaiz, Esther, Miar, Ana, Bridges, Esther, Prasad, Naveen, Hatch, Stephanie B., Ebner, Daniel, Lawrie, Charles H., Harris, Adrian L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8344147/
https://www.ncbi.nlm.nih.gov/pubmed/34353313
http://dx.doi.org/10.1186/s12885-021-08616-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8344147/
https://www.ncbi.nlm.nih.gov/pubmed/34353313
http://dx.doi.org/10.1186/s12885-021-08616-8

Ejemplares similares